GLP-1 drugs like semaglutide and tirzepatide work primarily through the brain, amplifying your body's natural "stop eating" signals rather than simply forcing you to eat less. While headlines often focus on dramatic weight loss, emerging research from major medical institutions reveals a more complex picture: these medications affect multiple organ systems, show unexpected benefits for people with HIV, and may help with conditions like smoking addiction and liver disease. However, questions about long-term use and global access remain unanswered .

How Do GLP-1 Drugs Actually Change Your Brain and Eating Behavior?

The popular understanding of GLP-1 medications is that they suppress appetite, but neuroscientists at the University of Alabama at Birmingham are uncovering something more nuanced. These drugs don't simply turn off hunger; they strengthen the brain circuits that tell you when you're full. "Preclinical studies show that, if you restrict the action of GLP-1 drugs to the brain alone, you still see reduced food intake," explained Andrew Hardaway, a neuroscientist in the Department of Psychiatry and Behavioral Neurobiology at UAB. "That tells us appetite suppression is fundamentally a brain-mediated effect" .

"They essentially amplify the body's own satiety cues. You're not just choosing to eat less. The signals that tell you you're full become stronger and more effective," said Andrew Hardaway.

Andrew Hardaway, Ph.D., Neuroscientist, Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham

The brain contains multiple overlapping circuits that regulate eating. Some promote food seeking and consumption, while others act as brakes, signaling when to stop eating. GLP-1 drugs strengthen those natural "stop" signals. They work at multiple points in the eating process: reducing cravings and food-seeking behavior before a meal even begins, and then increasing feelings of fullness once eating starts .

Many patients report that foods they once craved no longer hold the same appeal while taking GLP-1 drugs. This effect may be tied to changes in the brain's reward system. Normally, eating, especially calorie-dense or highly palatable food, triggers the release of dopamine, a neurotransmitter associated with reward and motivation. GLP-1 drugs blunt that dopamine response, making food less rewarding overall .

What Unexpected Health Benefits Are Researchers Discovering Beyond Weight Loss?

One of the most striking findings from recent research is that GLP-1 drugs appear to help people living with HIV manage weight gain and metabolic abnormalities, conditions that become increasingly concerning as people with HIV age. Three major studies presented at the Conference on Retroviruses and Opportunistic Infections in 2026 examined real-world use of these medications among people with HIV .

A study from George Washington University assessed outcomes among 362 people with HIV who took GLP-1 medications for at least six months. Most had diabetes (82%) and/or obesity (78%). Nearly one in five (19%) lost 5% to 10% of their baseline body weight, and 11% lost 10% or more. The most commonly used GLP-1 was semaglutide (50%), and the average time on the drugs was 3.2 years .

Research from the University of California San Diego looked specifically at tirzepatide, which targets both GLP-1 and another gut hormone called glucose-dependent insulinotropic polypeptide (GIP). In an analysis of 61 people with HIV, the overall mean weight loss was about 14% of baseline body weight at 12 months, slightly less than the 17% loss seen in the general population. Participants also saw significant reductions in hemoglobin A1C (a measure of blood sugar control) and blood pressure, improved HDL "good" cholesterol levels, and lower 10-year cardiovascular disease risk scores .

Beyond weight and blood sugar, researchers discovered additional health benefits that extend far beyond obesity treatment:

• Smoking Reduction: Among 204 people with HIV who reported smoking when they started semaglutide, smoking fell by an average of 2.7 cigarettes per day, representing a 26% decrease in daily cigarette consumption .
• Liver Health Improvement: Semaglutide was associated with reduced liver fibrosis scores in participants with moderate to advanced liver stiffness, addressing metabolic dysfunction-associated steatotic liver disease (MASLD), a growing concern for people with HIV .
• Mental Health Stability: A study of 354 HIV-positive people starting semaglutide found that the drug was not associated with overall worsening of depressive symptoms among those with absent, mild, moderate, or severe depression at baseline, addressing early safety concerns .

Why Do These Drugs Work on So Many Different Body Systems?

The reason GLP-1 drugs affect so many different aspects of health comes down to how they work at the cellular level. Newer medications like tirzepatide activate more than one hormonal pathway, which creates synergistic effects. "A drug or hormone can only act where its receptor is expressed," explained Kirk Habegger, professor in the Division of Endocrinology, Diabetes and Metabolism at UAB. "When you activate multiple receptors that are expressed in different tissues, or even on the same cells, you don't just add effects. You get synergy" .

"When you activate multiple receptors that are expressed in different tissues, or even on the same cells, you don't just add effects. You get synergy," said Kirk Habegger.

Kirk Habegger, Ph.D., Professor, Division of Endocrinology, Diabetes and Metabolism, University of Alabama at Birmingham

GLP-1 and GIP receptors are found in the brain, alongside fat cells, pancreatic beta cells, and other tissues involved in metabolism. Activating both receptors can improve insulin secretion, enhance fat metabolism, and amplify appetite suppression. Much of the benefit appears to come from the central nervous system, but GIP receptors are also expressed on adipocytes (fat cells), which gives these drugs additional metabolic effects .

One of the most striking findings from large clinical trials is that GLP-1 drugs reduce the risk of heart attacks, strokes, and cardiovascular death, and they also improve metabolic liver disease. Yet cardiomyocytes (the main muscle cells of the heart) and hepatocytes (liver cells) do not appear to express GLP-1 or GIP receptors in significant amounts. The answer is probably both direct and indirect. GLP-1 receptors are expressed on certain immune cells, including T-cells. Chronic inflammation plays a key role in fibrosis and organ damage in the heart and liver. Reducing inflammatory signaling may protect tissues even without acting directly on muscle or liver cells .

What's Next: The Future of GLP-1 Research and Innovation?

The pace of innovation in this field is accelerating rapidly. In December 2025, the FDA approved an oral version of GLP-1 semaglutide. Multisite research, including research at UAB, shows that oral semaglutide is nearly as effective as the widely used injectable version for treating obesity, delivering about 13.7% average weight loss over 64 weeks .

Researchers are already testing triple-agonist drugs, such as retatrutide, which target GLP-1, GIP, and glucagon receptors. Early data suggest even greater weight loss and metabolic benefits. Scientists have even begun work on a five-receptor agonist that combines GLP-1 and GIP with activation of nuclear hormone receptors known as PPARs, targets once used by diabetes drugs like rosiglitazone and pioglitazone. The hope is that peptide-based therapies could deliver those benefits more precisely and with fewer side effects .

Despite their effectiveness, GLP-1 drugs do not work equally well for everyone. Some patients experience dramatic weight loss, while others see more modest changes. Now that millions of people are taking these medications far beyond the scope of clinical trials, researchers are beginning to understand why. "We're learning things we couldn't have learned before," noted Hardaway. "That variation is driving a lot of interest in understanding the underlying biology" .

One unanswered question is whether long-term use could lead to reduced responsiveness over time. Receptors can internalize or downregulate with prolonged stimulation, but researchers don't yet know if this happens with GLP-1 drugs in real-world use .

What Are the Key Barriers to Making GLP-1 Drugs Available Globally?

While the scientific evidence for GLP-1 drugs is compelling, access remains a major challenge. Dr. Todd Brown of Johns Hopkins Medicine, speaking at the Conference on Retroviruses and Opportunistic Infections, noted that "with the exception of antiretroviral therapy, I can't think of another class of medications where there has been so much buzz." He concluded that the enthusiasm is warranted, but "global access will be a major challenge" .

In real-world use, access barriers are already evident. In the University of California San Diego study of tirzepatide among people with HIV, more than a quarter (26%) stopped taking the medication before completing one year, mostly due to either side effects or insurance issues .

The research community recognizes that for GLP-1 drugs to truly be a "global game-changer," they need to be both accessible and affordable. This is particularly important for people living with HIV in resource-limited settings, where weight gain and metabolic abnormalities are becoming increasingly common as people live longer with the virus .